Grants and Contributions:
This investment will allow the company to advance their COVID-19 therapeutic candidate (EB05) through Phase II clinical trials, in hopes of advancing to Phase III. This project anticipates the creation of 6 new full-time jobs and will maintain 8 full-time jobs within Canada.
Please note this update includes a change to improve standardization of reporting across projects. The end date was updated from the end of the work phase of the project (31/12/2028) to the current end date of the contract (31/12/2030). This is not an extension. The end date now reflects the entirety of the agreement duration, including the benefit phase and residual audit period. The original start date was updated to reflect the correct execution date.
Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.